AstraZeneca Will Establish Antibiotic Subsidiary With $40 Million
The big pharma – one of the few still investing in antibiotic research – will create a stand-alone subsidiary to focus exclusively on early-stage antibiotic development.
The big pharma – one of the few still investing in antibiotic research – will create a stand-alone subsidiary to focus exclusively on early-stage antibiotic development.